Da natriumoxybat metaboliseres af GHB dehydrogenase er der en potentiel risiko for interaktion med stoffer, som hæmmer dette enzym (f. eks. valproat, phenytoin eller ethosuximid).
Since sodium oxybate is metabolised by GHB dehydrogenase there is a potential risk of an interaction with drugs that stimulate or inhibit this enzyme (e. g. valproate, phenytoin or ethosuximide).